Laboratory methods for KRAS mutation analysis

References

• Wang HL, Lopategui J, Amin MB et al. KRAS mutation testing in human cancers: the pathologists role in the era of personalized medicine. Adv. Anat. Pathol.17, 23–32 (2010).
   PubMed Web of Science ®Google Scholar
• Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thoracic Soc.6, 201–205 (2008).
   Google Scholar
• Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. J. Mol. Diagn.10, 493–495 (2008).
   PubMed Web of Science ®Google Scholar
• American Cancer Society. 2010 Cancer Facts and Figures. ACS, GA, USA (2010).
   Google Scholar
• Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer-an update of recent developments. Head Neck Oncol.2, 8–13 (2010).
   PubMedGoogle Scholar
• Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol.26(3), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab and advanced colon cancer. N. Engl. J. Med.359, 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Van Custem E, Lang I, D’haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J. Clin. Oncol.26, 5S (2008).
   Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab. J. Clin. Oncol.26, 178S (2008).
   Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Shutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol.19, 508–515 (2008).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25, 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer96, 1166–1169 (2007).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colon cancer. J. Clin. Oncol.26, 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colon cancer. J. Clin. Oncol.26, 5705–5712 (2008).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol.27, 2091–2095 (2009).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Guidelines on Colon and Rectal Cancers. NCCN, PA, USA (2008).
   Google Scholar
• Miller VA, Riely GJ, Zakowski MF et al. Molecular characterization of bronchioloavlveolar carcinoma and adenocarcinoma, brochioloavelolar carcinoma subtype, predict response to erolotinib. J. Clin. Oncol.26, 1472–1478 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PA et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol.24, 5034–5042 (2006).
   PubMed Web of Science ®Google Scholar
• Han SW, Kim TY, Leon YK et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res.12, 2538–2544 (2006).
   PubMed Web of Science ®Google Scholar
• Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res.13, 2890–2896 (2007).
   PubMed Web of Science ®Google Scholar
• Jimeno A, Messersmith WA, Hirsch FR et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol.27, 1130–1135 (2009).
   PubMed Web of Science ®Google Scholar
• Van Krieken JH, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an european quality assurance program. Virchows Archiv.453, 417–431 (2008).
   PubMed Web of Science ®Google Scholar
• Neumann J, Zeindl-Eberhart E, Kirchner T et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Prac.205, 858–862 (2009).
   PubMed Web of Science ®Google Scholar
• Inamura K, Takeuchi K, Togashi Y et al. EML4–ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset. Modern Pathol.22, 508–515 (2009).
   PubMed Web of Science ®Google Scholar
• Clayton SJ, Scott FM, Walker J et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutaion detection using ARMS allele-specific amplification. Clin. Chem.46, 1929–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Lang AH, Drexel H, Geller-Rhomberg S et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J. Mol. Diagn.13, 23–28 (2011).
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Brahmandam M et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J. Mol. Diagn.7, 413–421 (2005).
   PubMed Web of Science ®Google Scholar
• Tsiatis AC, Norris-Kirby A, Rich RG et al. Comparison of sanger sequencing, pyrosequencing, and melt curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J. Mol. Diagn.12, 425–432 (2010).
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Akagi L, Reddy PL, Joseph L, Tait JF. COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. BMC Clin. Pathol.10, 1–10 (2010).
   PubMedGoogle Scholar
• TheraScreen® Package Insert, DsX, Manchester, UK (2009).
   Google Scholar
• PyroMark® Package Insert, Qiagen, Valencia, CA, USA (2010).
   Google Scholar
• Angulo B, Garcia-Garcia E, Martinez R et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J. Mol. Diagn.12, 292–299 (2010).
   PubMed Web of Science ®Google Scholar
• Whitehall V, Tran K, Umapathy A et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J. Mol. Diagn.11, 543–552 (2009).
   PubMed Web of Science ®Google Scholar
• Weichart W, Schewe C, Lehmann A et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J. Mol. Diagn.12, 35–42 (2010).
   PubMed Web of Science ®Google Scholar
• Oliner K, Juan T, Suggs S et al. A comparability study of 5 commercial KRAS tests. Diagn. Pathol.5, 23–29 (2010).
   PubMed Web of Science ®Google Scholar
• De Roock W, Jonker D, Di Nicolantonio F et al. Association of KRAS G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA304, 1812–1820 (2010).
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res.16, 790–799 (2010).
   PubMed Web of Science ®Google Scholar
• Ogino S, Kawasaki T, Brahmandan M et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J. Mol. Diagn.4, 413–421 (2005).
   Google Scholar
• Samowitz W, Curtin K, Schaffer P et al. Relationship of Ki-ras mutation in colon cancer to tumor location, stage and survivorship: a population based study. Cancer Epidemiol. Biomarkers Prev.9, 1193–1197 (2000).
   PubMed Web of Science ®Google Scholar
• Cai L, Kam-Morgan L, Kallam E et al. Detection of KRAS oncogene mutations using PCR and pyrosequencing methods. Presented at: ASCO–NCI–EORTC Annual Meeting: Molecular Markers in Cancer. Brussels, Belgium, 14–17 October 2009.
   Google Scholar
• Faulkner NE, Da Silva MM, Heim RA et al. KRAS mutation analyses of >16,500 colorectal carcinomas. Presented at: ASCO–NCI–EORTC Annual Meeting: Molecular Markers in Cancer. Brussels, Belgium, 18–20 October 2010.
   Google Scholar
• Moses W, Weng J, Sansano I et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine needle aprirate biopsies. World J. Surg.34, 2589–2594 (2010).
   PubMed Web of Science ®Google Scholar
• Lapakos O, Gologan O, Liu Y et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod. Pathol.19, 907–913 (2006).
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Schmidt K, Donehower R et al. Analysis of circulating tumor DNA to confirm somatic mutations. J. Natl Cancer Inst.101, 1284–1287 (2009).
   PubMed Web of Science ®Google Scholar